Global Epinephrine Autoinjector Market 2018-2024 – Increased Focus Towards the Development of Chlorofluorocarbon (CFC) Free Epinephrine Auto-Injectors by Leading Players – ResearchAndMarkets.com

The “Epinephrine
Autoinjector Market: Global Industry Analysis, Trends, Market Size and
Forecasts up to 2024” report has been added to ResearchAndMarkets.com’s

The report predicts the global epinephrine autoinjector market to grow
with a CAGR of 13.8% over the forecast period of 2018-2024.

The major factors contributing to the growth of the epinephrine
autoinjectors includes, the growing prevalence of allergies, demand for
autoinjectors instead of conventional syringes and increased focus of
the major leading players towards development of chlorofluorocarbon
(CFC) free epinephrine auto-injectors. However, high cost of
autoinjectors and regulatory hurdles can hinder the epinephrine growth

Moreover, Patient’s assistance programs carried out for uninsured
person, continuous product modification and demand for automatic
injection devices to further create growth opportunities for the
epinephrine autoinjectors market.

Key Topics Covered

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Global Epinephrine Autoinjector Market Overview

3.1. Introduction

3.2. Market Dynamics

3.3. Porter’s Five Forces Analysis

3.4. Growth Matrix Analysis

3.5. Competitive Landscape in the Global Epinephrine Autoinjector Market

4. Global Epinephrine Autoinjector Market by Dosage

4.1. 0.15 Mg Epinephrine Autoinjector

4.2. 0.3 Mg Epinephrine Autoinjector

4.3. 0.5 Mg Epinephrine Autoinjector

5. Global Epinephrine Autoinjector Market by End-User

5.1. Hospital

5.2. Clinics

5.3. Individual

6. Global Epinephrine Autoinjector Market by Region 2018-2024

6.1. North America

6.2. Europe

6.3. Asia-Pacific

6.4. RoW

7. Company Covered

7.1. Amedra Pharmaceuticals LLC

7.2. Mylan Inc.

7.3. ALK Abello

7.4. Sanofi SA

7.5. Lincoln Medical Ltd

7.6. Teva Pharmaceuticals Ltd

7.7. Antares Pharma Inc.

7.8. Hospira Inc.

For more information about this report visit https://www.researchandmarkets.com/research/rgwgf5/global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619006389/en/